产品
编 号：F755324
分子式：C27H32N8O2
分子量：500.6
分子式：C27H32N8O2
分子量：500.6
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2750001-23-9
产品详情
生物活性：
AZD0095 is a selective and orally active MCT4 inhibitor (IC50: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205).
体内研究：
AZD0095 (100 mg/kg, 口服，一天两次) 与 Cediranib.html" class="link-product" target="_blank">Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长。Animal Model:Murine NCI-H358 xenograft
Dosage:100 mg/kg together with Cediranib (3 mg/kg)
Administration:Oral administration (p.o.)
Result:Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.
体外研究：
AZD0095 (0-50 μM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖，IC50 为 26 nM。
AZD0095 is a selective and orally active MCT4 inhibitor (IC50: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205).
体内研究：
AZD0095 (100 mg/kg, 口服，一天两次) 与 Cediranib.html" class="link-product" target="_blank">Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长。Animal Model:Murine NCI-H358 xenograft
Dosage:100 mg/kg together with Cediranib (3 mg/kg)
Administration:Oral administration (p.o.)
Result:Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.
体外研究：
AZD0095 (0-50 μM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖，IC50 为 26 nM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备